

Genasys Inc.
Condensed Consolidated Balance Sheets
(Unaudited - in thousands)

	September 30,	
	2022	2021
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 12,736	\$ 13,167
Short-term marketable securities	6,397	5,686
Restricted cash	100	279
Accounts receivable, net	6,744	7,682
Inventories, net	6,008	6,416
Prepaid expenses and other	3,577	2,255
Total current assets	35,562	35,485
Long-term marketable securities	781	1,875
Long-term restricted cash	823	1,082
Deferred tax assets, net	7,373	8,039
Property and equipment, net	1,757	1,755
Goodwill	10,118	23,834
Intangible assets, net	10,505	12,804
Operating lease right of use asset	4,541	4,862
Prepaid expenses and other - noncurrent	394	392
Total assets	\$ 71,854	\$ 90,128
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 2,334	\$ 2,160
Accrued liabilities	12,083	14,111
Notes payable, current portion	-	296
Operating lease liabilities, current portion	948	899
Total current liabilities	15,365	17,466
Other liabilities, noncurrent	907	995
Operating lease liabilities, noncurrent	5,189	5,709
Total liabilities	21,461	24,170
Total stockholders' equity	50,393	65,958
Total liabilities and stockholders' equity	\$ 71,854	\$ 90,128

Genasys Inc.
Condensed Consolidated Statements of Operations
(Unaudited - in thousands, except per share amounts)

	Three months ended September 30,		Years ended September 30,	
	2022 (unaudited)	2021 (unaudited)	2022 (unaudited)	2021 (unaudited)
Revenues	\$ 16,038	\$ 15,047	\$ 54,035	\$ 47,003
Cost of revenues	8,378	7,348	27,693	23,577
Gross profit	<u>7,660</u>	<u>7,699</u>	<u>26,342</u>	<u>23,426</u>
	47.8%	51.2%	48.7%	49.8%
Operating expenses:				
Selling, general and administrative	5,568	5,493	21,688	17,424
Impairment of goodwill	13,162	-	13,162	-
Research and development	1,696	1,502	7,023	4,918
Total operating expenses	<u>20,426</u>	<u>6,995</u>	<u>41,873</u>	<u>22,342</u>
(Loss) income from operations	(12,766)	704	(15,531)	1,084
Other income and expense, net	48	(5)	60	54
(Loss) income before income taxes	<u>(12,718)</u>	<u>699</u>	<u>(15,471)</u>	<u>1,138</u>
Income tax (benefit) expense	1,108	(72)	741	434
Net (loss) income	<u>\$ (13,826)</u>	<u>\$ 771</u>	<u>\$ (16,212)</u>	<u>\$ 704</u>
Net (loss) income per common share:				
Basic	<u>\$ (0.38)</u>	<u>\$ 0.02</u>	<u>\$ (0.44)</u>	<u>\$ 0.02</u>
Diluted	<u>\$ (0.38)</u>	<u>\$ 0.02</u>	<u>\$ (0.44)</u>	<u>\$ 0.02</u>
Weighted average common shares outstanding:				
Basic	<u>36,599</u>	<u>36,222</u>	<u>36,495</u>	<u>34,409</u>
Diluted	<u>36,599</u>	<u>37,252</u>	<u>36,495</u>	<u>35,589</u>
Reconciliation of GAAP measures to non-GAAP measures				
Net (loss) income	\$ (13,826)	\$ 771	\$ (16,212)	\$ 704
Other income and expense, net	(48)	5	(60)	(54)
Income tax (benefit) expense	1,108	(72)	741	434
Impairment of goodwill	13,162	-	13,162	-
Depreciation and amortization	636	644	2,556	1,597
Stock based compensation	577	468	2,227	1,424
Adjusted EBITDA	<u>\$ 1,609</u>	<u>\$ 1,816</u>	<u>\$ 2,414</u>	<u>\$ 4,105</u>